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Consequently there is a need to establish new treatments to prevent relapse. A promising approach is to augment the anti-tumor immune response in these patients; however, it is well established that overexpression of immunosuppressive molecules such as CD200 on the surface of AML cells directly suppresses the antitumor response. [2] [3] [4] Nevertheless, blocking CD200:CD200R, only partially restores T-cell activity, suggesting that alternative immunosuppressive mechanisms need to be explored if the antitumor response in AML is to be optimally exploited. 5 Recently, promising clinical outcomes using humanized antibodies targeting PD-1 have been reported for melanoma and even for non-small cell lung cancer. 6 PD-1 suppresses immunological function via interaction with its cognate ligand PD-L1 (aka B7-H1, CD274) and previous work has indicated that PD-L1 may also suppress immunological function in AML. 7, 8 Here we investigate whether the PD-1:PD-L1 axis cooperates with CD200 in mediating immunosuppression in AML patients.
Initially, we investigated whether CD200 and PD-L1 were coexpressed in AML blasts. Gene expression data from 158 AML diagnostic samples were analyzed and stratified into CD200 hi and CD200 lo based on upper and lower quartiles of expression. 3 As shown in Figure 1a , CD200 hi AML patients had 10-fold higher levels of PD-L1 mRNA compared to CD200 lo patients. Flow cytometric analysis of CD200 and PD-L1 protein expression on AML blast cells confirmed this association at the protein level (Figure 1b) . Taken together, these data establish that the immunosuppressive ligands CD200 and PD-L1 are coexpressed on patient AML blast cells, indicating that CD200 and PD-L1 could cooperate in AML cell mediated immunosuppression. A possible explanation for this observation is that CD200 and PD-L1 may be upregulated by AML as an adaptive mechanism following a T cellmeditated immune response. 9 In common with other malignancies, robust CD8 + T-cell responses are thought to be important in AML antitumor immunity. 10 We previously demonstrated that CD200 overexpression in AML suppresses memory CD8 + T-cell effector function. 4 To investigate whether CD200 together with PD-L1 had the potential to inhibit CD8 + T-cell effector function, we first determined whether these cells expressed the respective negative coreceptors CD200R and PD-1 in AML patients. This analysis showed expression of both CD200R and PD-1 on CD8 + T cells from AML patients, interestingly, higher expression levels of PD-1 were observed for CD200 hi AML patients ( Supplementary Figures 2 and  3 Figure 4) .
The above data suggested that stimulation of the CD200: CD200R immune-axis may have the capacity to induce PD-1 expression on target CD8 + T cells. To investigate this, we assessed whether CD200:CD200R stimulation was directly capable of mediating PD-1 up-regulation on target CD8 + T cells. We carried out a refined coculture assay in which a CD8 + T cell clone (7E7) 13 Figure 1. Assessment of CD200 and PD-L1 coexpression on AML patient blasts. The coexpression of CD200 and PD-L1 in AML patients was compared at the transcript level by microarray and at the protein level by flow cytometry. (a) Affymetrix gene expression data (U133 plus_2.0) from 158 AML patients was analyzed using GeneSpring v12.6 (Agilent Technologies). Gene expression data were normalized to median gene expression and expressed as Log 2 as previously described. 16 AML patients (Supplementary Table 1 ) were stratified to CD200 hi and CD200 lo (probe set; 209582_s_at) based on normalized expression level (n = 39 for each) as previously described. 4 Data were consistent for the alternative probe for CD200, 209583_s_at (not shown). Data illustrate a significant increase in PD-L1 normalized expression (probe sets; 223834_s_at and 227458_s_at) for CD200 hi AML patients (mean ± s. e). (b) The association between CD200 and PD-L1 expression level on AML patient blast cells isolated from peripheral blood was analyzed by flow cytometry. AML blast cells were identified through CD45/CD34 bivariate analysis as previously described. 2 The data illustrate a positive correlation between CD200 and PD-L1 protein expression (normalized mean fluorescence intensity; MFI) 2 Figure 5) . In these assays, 7E7 T-cell PD-1 expression was monitored by flow cytometry. Figure 2b illustrates that in the presence of CD200 + K562 cells, the frequency of PD-1 + 7E7 T cells was significantly increased 1.5-fold compared with 7E7 T cells cocultured with CD200 -K562 cells and exceeded the level of PD-1 up-regulation achieved through CD3/CD28 receptor costimulation of 7E7. To verify these data, a CD200 blocking antibody 3 was added to the CD200 + K562 7E7 T cell assay. The effect on 7E7 CD8 + T-cell activation of coculture with K562 cells expressing CD200 and/or PD-L1. This was assessed by secretion of TNFα (intracellular cytokine staining) 4 in CD3/CD28 activated 7E7 CD8 + T cells following coculture with K562 cells (n = 9). Data are mean ± 1 s.e. *P o0.05 analyzed by one-way ANOVA with Tukey's multiple comparison test. † Po 0.05 and † † P o0.01 analyzed by one-tailed paired t-test.
Letters to the Editor Figure 2c illustrates a significant reduction in the frequency of PD-1 + 7E7 T cells in the presence of the CD200 blocking antibody, demonstrating that PD-1 expression on target CD8 + T cells can be reduced through CD200:CD200R blockade in a CD200 hi setting. Taken together, our findings illustrate, for the first time, that CD200:CD200R interaction has the capacity to increase the frequency of PD-1 + CD8 + T cells. To investigate the consequences of CD200 and PD-L1 coexpression on T-cell activation, we created a series of K562 lines expressing CD200 or PD-L1 or both molecules in combination (Figure 2d) . The 7E7 CD8 + T-cell clone produces tumor necrosis factor alpha (TNFα) upon stimulation, 13 and was used as an endpoint for 7E7 T-cell activation in our assays. Figure 2e shows that both CD200 and PD-L1 induced a similar (450%) reduction in the frequency of activated 7E7 T cells (compared with cocultivation with K562 control cells expressing neither molecule); however, when both CD200 and PD-L1 were co-expressed 7E7 T-cell activation was almost ablated (~90% reduction). Moreover, the strength of the TNFα response was significantly reduced in coculture assays where either CD200 or PD-L1 were present, indicating a direct effect at the level of CD8 + T-cell function (Supplementary Figure 6 ). These data demonstrate that CD200:CD200R and PD-L1:PD-1 engagement on T cells can act in tandem to produce a greater immunosuppressive effect on CD8 + T cells when expressed on leukemia cells. This is of particular importance in AML, where both CD200 and PD-L1 are frequently co-expressed on AML cells. The expression level of CD200 on T cells was identical for CD200 hi and CD200 lo AML and is unlikely to contribute to the immunosuppressive effects observed, at least for newly diagnosed patients (Supplementary Figure 7) . Previous studies in AML indicate that multiple immunosuppressive mechanisms may work in conjunction; for example coexpression of PD-1 and the negative regulatory receptor, Tim-3, identify a dysfunctional CD8 + T-cell population; 14 whereas in other contexts it has been shown that dual blockade of PD-L1: PD-1 and CTLA-4 is required to restore CD8 + effector T-cell antitumor responses. 15 Here we propose that stimulation of the CD200:CD200R immune-axis augments the frequency of PD-1 +
CD8
+ T cells and that these in turn engage with PD-L1 on AML blasts, exacerbating immunosuppressive effects. Interestingly in AML, overexpression of both CD200 and PD-L1 in have been linked to a worse patient prognosis,. 16, 17 Given the recent progress in PD-1 targeted immunotherapy (for example Nivolumab and Pembrolizumab) and also Samalizumab for CD200:CD200R blockade, 6, 18 we propose a novel CD200/PD-L1 immunotherapeutic synapse in AML which should be targeted by combining CD200:CD200R and PD-L1:PD-1 blockade for future immunotherapy of AML.
